Cardiovasculaire Geneeskunde.nl

New targets in lipid management

Slides (presentatie) - Dec. 12, 2011

New targets in lipid management


Deze presentatie is gehouden door:
Prof. dr. John Kastelein, internist
Academisch Medisch Centrum, Amsterdam

tijdens het symposium ter gelegenheid van de oraties van prof. dr. E.S.G. Stroes en prof. dr. S. Middeldorp op 16 september 2011

 


Bekijk de presentatie

klik voor bekijken op onderstaande afbeeldingen

 


New targets in lipid management

Novel Approaches to Modify Lipids and Lipoproteins

Statin Prescription in the UK

Percentage of the UK-population with TC > 5 mmol/l

All-Cause Mortality in the UK in those < 75 Years

New Approaches to LDL Reduction

Mipomersen: Apo B-100 as a Target

Overview of Mipomersen

Antisense

Heterozygous Familial Hypercholesterolemia

Mipomersen Significantly Reduced LDL-C

Distribution of LDL-C % Change From Baseline

The Rationale

Selective Thyroid Receptor Agonist Provides New Treatment Opportunities

Eprotirome is…

Eprotirome Monotherapy Efficiently Lowers LDL-C

LDL-C Mean % Change from Baseline

PCSK9 Rapid Pace of Research

New Approaches for Raising HDL

CETP Levels and CAD risk

Anacetrapib Dose Ranging Study

Future

Niacin Flushing Pathway

An Overview of the Niacin-Induced Flushing Pathway

Factorial Study: Lipid Efficacy

HPS2-THRIVE

ApoA1 Based Therapies

Cerenis HDL (CER-001)Homogeneous Drug Product

CER-001 Mobilizes Cholesterol in Rabbits

CHI SQUARE Study Design

CHI-SQUARE Study Design

IVUS clinical trial using selective delipidated HDL

IVUS Clinical Trial Using Selective Delipidated HDL

Results of the IVUS Clinical Trial Using Selective Delipidated HDL

New Approaches for Reduction of TG rich Lipoproteins

Apolipoprotein C-III Key Regulator of Serum Triglyceride Levels

Dose-dependent Reduction in Hepatic ApoC-III mRNA Levels

Changes in Major Lipid Classes Over 12 Weeks in HTG Rhesus Plasma

New Approaches for Reduction of Inflammation

The Balance of IL-1 and IL-1Ra

Canakinumab

Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Conclusion

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: